Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.
- 1 March 1987
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 5 (3), 436-440
- https://doi.org/10.1200/jco.1987.5.3.436
Abstract
A phase II trial of 6 months of alternating etoposide plus cisplatin (EP) and cyclophosphamide, vinblastine, actinomycin D, bleomycin, cisplatin (VAB-6) was conducted in 41 evaluable patients in an attempt to improve the treatment results in those patients considered to have "poor-risk" germ cell tumors (GCT). Eight of 14 (57%) patients with mediastinal and retroperitoneal GCTs achieved complete remission (CR), and five (36%) remain alive and free of disease. Fourteen of 27 patients (52%) with poor-risk testicular cancer achieved CR, and ten (37%) remain alive and free of disease. Two patients with seminoma, one each with a testicular and extragonadal primary tumor, achieved durable CRs. Toxicity was tolerable, but greater than that of VAB-6 alone. The response and survival of the 39 patients with nonseminomatous tumors were found to be identical to the results of 29 patients with nonseminomatous GCTs and poor-risk characteristics who were treated with VAB-6 alone. Thus, this 6-month schedule of alternating months of chemotherapy is not recommended for patients with poor-risk GCTs. Patients with such tumors should be referred to centers conducting prospective trials, so that research seeking better therapy may continue.This publication has 8 references indexed in Scilit:
- VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.Journal of Clinical Oncology, 1986
- Prognostic factors for favorable outcome in disseminated germ cell tumors.Journal of Clinical Oncology, 1986
- The results of chemotherapy for extragonadal germ-cell tumors in the cisplatin era: the Memorial Sloan-Kettering Cancer Center experience (1975 to 1982).Journal of Clinical Oncology, 1985
- Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial.Journal of Clinical Oncology, 1985
- Chemotherapy of extragonadal germ cell tumors.Journal of Clinical Oncology, 1985
- Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumorsAmerican Journal Of Medicine, 1985
- Treatment and surgical staging of testicular and primary extragonadal germ cell cancerJAMA, 1983
- MULTIVARIATE-ANALYSIS OF PROGNOSTIC VARIABLES IN PATIENTS WITH METASTATIC TESTICULAR CANCER1983